Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Systemic treatment with recombinant human epidermal growth factor accelerates healing of sclerotherapy-induced esophageal ulcers and prevents esophageal stricture formations in pigs (1994)
    Springer
    Digestive diseases and sciences 39 (1994), S. 2671-2678 
    Details
    ISSN: 1573-2568
    Keywords: epidermal growth factor ; sclerotherapy ; esophageal ulcers
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Human epidermal growth factor (EGF), a small polypeptide (6 kDa) with mitogenic properties, has been implicated in the protection of gastrointestinal mucosal integrity. The efficacy of EGF in the prevention and healing of sclerotherapy-induced esophageal lesions was investigated in 24 minipigs with surgically induced portal hypertension. In addition, the effect of EGF on intragastric acidity and pharmacokinetics was investigated as possible means to explain its protective mechanism of action. The animals underwent three weekly sessions of sclerotherapy with polidocanol 2% and were concomitantly and for an additional three weeks treated with either placebo or EGF administered paravenously in the esophagus and/or subcutaneously. The subcutaneous treatment with EGF significantly (P〈0.05) reduced esophageal stricture and scar formations associated with sclerotherapy. Gastric pH values were significantly (P〈0.01) elevated only in animals receiving subcutaneous injections of EGF. Furthermore, the subcutaneous administration of EGF was associated with unexpected prolonged plasma concentration of the peptide. These results suggest a possible clinical value of EGF as an adjunctive treatment with the sclerotherapy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02087708
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Chronic treatment with epidermal growth factor causes esophageal epithelial hyperplasia in pigs and rats (1995)
    Springer
    Digestive diseases and sciences 40 (1995), S. 2717-2723 
    Details
    ISSN: 1573-2568
    Keywords: pigs ; rats ; lectins ; immunoreactivity ; esophageal epithelium
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Epidermal growth factor (EGF) is an important factor for maintaining the esophageal functional integrity. Goettingen minipigs were treated with either placebo or subcutaneous EGF (30 μg/kg/day) for four weeks. Wistar rats were treated with either placebo or subcutaneous EGF (150 μg/kg/day) for four weeks. At sacrifice, esophageal samples were obtained for histology, immunochemistry, and lectin characterization. In pigs, the thickness of the esophageal epithelium was almost doubled in the EGF-treated animals. Characterization with lectins revealed a normal pattern of differentiation. Subcutaneously administered EGF was visualized on cells located basally in the esophageal epithelium. In rats EGF-treatment increased the esophageal volume of the epithelium, the lamina propria of the mucosa, and the subnucosa. In conclusion, systemic EGF challenge induces growth of the esophageal epithelium with an unaltered pattern of differentiation. This supports previous studies demonstrating a beneficial effects of systemic EGF-treatment on sclerotherapyp-induced esophageal damage.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02220465
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...